Office of Commercialization and Economic Development
Office of Technology Commercialization

Hematopoietic Protection Against Chemotherapy and Ionizing Radiation Using Selective Cyclin-Dependent Kinase 4/6 Inhibitors

Technology #09-0009

An inhibitor of CDK4/6 significantly reduced radiation toxicity in mice treated with ionizing radiation. CDK4/6 inhibitors have been developed for a number of CDK4/6 dependent cancers. CDK4/6 inhibitors can also ameliorate the dose-limiting toxicities of radiation therapy and chemotherapy in CDK4/6-indepdendent tumors through the induction of “pharmacological quiescence".

Advantages:

· Hematopoietic protection from lethal doses of ionizing radiation

· Prevent bone marrow from myelosuppression induced by cytotoxic chemotherapy

· Reduce treatment toxicity without compromising the therapeutic response

· CDK4/6 inhibitors are clinically approved